Built on the Avance III HD IVDr nuclear magnetic resonance spectroscopy platform, this methodology has obtained dual FDA and CE certification and is recommended by a number of authoritative professional guidelines. The technology can be widely applied to the precise early warning of cardiovascular and cerebrovascular diseases, individualized selection and dynamic efficacy monitoring of lipid-lowering drugs, and systematic health assessment of the body's seven functional systems, offering a new technical means for precise clinical decision-making. Meanwhile, this method demonstrates significant value in clinical research on metabolic syndrome, cancer, diabetes and kidney disease, providing high-quality data support for disease mechanism research and risk stratification, and serving as an important technical pillar of ProteinT's "gene-protein-metabolite" multi-omics platform to advance and deepen the precision medicine system.

Leveraging its powerful technology platform to advance clinical scientific research, ProteinT serves many top-tier hospitals and research institutes across China, has completed over one hundred research projects and supported the publication of over one hundred papers. We look forward to more scientific research collaborations that spark more cutting-edge technologies and achievements.